Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.
Trends Pharmacol Sci. 2016 Dec;37(12):1009-1028. doi: 10.1016/j.tips.2016.09.005. Epub 2016 Oct 10.
Antibody-based therapies have garnered considerable success in recent years. This is due to the availability of strategies to successfully engineer antibodies into humanized forms, better understanding of the biological processes involved in cancer development, the availability of novel recombinant antibody formats, better antibody selection platforms, and improved antibody conjugation methodologies. Such achievements have led to an explosion in the generation of antibodies and antibody-associated constructs for the treatment of cancer and other diseases. In this review, we critically assess recent trends in the development and applications of bispecific antibodies (bsAbs), antibody-drug conjugates (ADCs), and immune checkpoint inhibitors (ICIs) as cancer therapeutics. We also highlight recent US FDA approvals and clinical trials of antibody-based cancer therapies.
近年来，基于抗体的疗法取得了巨大的成功。这归因于成功地将抗体工程化为人类化形式的策略、对癌症发展中涉及的生物学过程的更好理解、新型重组抗体形式的可用性、更好的抗体选择平台以及改进的抗体偶联方法学。这些成就导致了用于治疗癌症和其他疾病的抗体和抗体相关构建体的大量产生。在这篇综述中，我们批判性地评估了双特异性抗体（bsAbs）、抗体药物偶联物（ADCs）和免疫检查点抑制剂（ICIs）作为癌症治疗药物的最新发展和应用趋势。我们还强调了最近美国 FDA 批准的和正在进行的抗体类癌症疗法的临床试验。
